• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

骨髓增生异常综合征的管理：2008年更新版

Management of myelodysplastic syndromes: 2008 update.

作者信息

Scott Bart L, Estey Eli

机构信息

University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.

出版信息

Oncology (Williston Park). 2008 Nov 15;22(12):1344-52.

PMID:19086598
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2647329/
Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic disorders characterized by low blood counts and a tendency to progress to acute myeloid leukemia. Treatment options have increased over the past 10 years, and many new agents are currently being investigated. In this article, we review the diagnosis of MDS, prognostic systems, and treatment options, including supportive care, erythropoiesis-stimulating agents, antithymocyte globulin, lenalidomide, azacitidine, decitabine, intensive chemotherapy, and hematopoietic cell transplantation.

摘要

骨髓增生异常综合征（MDS）是一组异质性造血系统疾病，其特征为血细胞计数低以及有进展为急性髓系白血病的倾向。在过去10年中，治疗选择有所增加，目前许多新型药物正在研究中。在本文中，我们综述了MDS的诊断、预后系统和治疗选择，包括支持性治疗、促红细胞生成剂、抗胸腺细胞球蛋白、来那度胺、阿扎胞苷、地西他滨、强化化疗和造血细胞移植。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/2647329/3062bb0da984/nihms-86958-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/2647329/7a2af9904d1d/nihms-86958-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/2647329/8a96723c4796/nihms-86958-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/2647329/74d6a53f4deb/nihms-86958-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/2647329/69a5dc3e37d2/nihms-86958-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/2647329/3062bb0da984/nihms-86958-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/2647329/7a2af9904d1d/nihms-86958-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/2647329/8a96723c4796/nihms-86958-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/2647329/74d6a53f4deb/nihms-86958-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/2647329/69a5dc3e37d2/nihms-86958-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/276f/2647329/3062bb0da984/nihms-86958-f0005.jpg

相似文献

1
Management of myelodysplastic syndromes: 2008 update.骨髓增生异常综合征的管理：2008年更新版
Oncology (Williston Park). 2008 Nov 15;22(12):1344-52.
2
How I treat patients with myelodysplastic syndromes.我如何治疗骨髓增生异常综合征患者。
Blood. 2009 Jun 18;113(25):6296-303. doi: 10.1182/blood-2008-09-038935. Epub 2009 Apr 21.
3
Risk-based management of myelodysplastic syndrome.骨髓增生异常综合征的基于风险的管理。
Oncology (Williston Park). 2007 Jan;21(1):43-54; discussion 57-8, 62.
4
Update on the pharmacotherapy for myelodysplastic syndromes.骨髓增生异常综合征的药物治疗进展。
Expert Opin Pharmacother. 2014 Sep;15(13):1811-25. doi: 10.1517/14656566.2014.937705. Epub 2014 Jul 31.
5
[Myelodysplastic syndromes: treatment strategy up-to-date].[骨髓增生异常综合征：最新治疗策略]
Rinsho Ketsueki. 2014 Jan;55(1):12-21.
6
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.骨髓增生异常综合征：2015 年诊断、风险分层和治疗更新。
Am J Hematol. 2015 Sep;90(9):831-41. doi: 10.1002/ajh.24102.
7
Myelodysplasia: new approaches.骨髓增生异常：新方法。
Curr Treat Options Oncol. 2013 Jun;14(2):156-69. doi: 10.1007/s11864-013-0224-x.
8
Novel therapies in low- and high-risk myelodysplastic syndrome.低危和高危骨髓增生异常综合征的新型治疗方法。
Expert Rev Hematol. 2019 Oct;12(10):893-908. doi: 10.1080/17474086.2019.1647778. Epub 2019 Jul 31.
9
Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society.成人骨髓增生异常综合征的管理：比利时血液学会指南
Acta Clin Belg. 2013 Jul-Aug;68(4):253-62. doi: 10.2143/ACB.3424.
10
Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.地西他滨分别联合复杂核型治疗急性髓系白血病和骨髓增生异常综合征。
Asian Pac J Cancer Prev. 2015;16(15):6627-32. doi: 10.7314/apjcp.2015.16.15.6627.

引用本文的文献

1
Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes.粒细胞和粒细胞巨噬细胞集落刺激因子用于新诊断的骨髓增生异常综合征患者。
Cochrane Database Syst Rev. 2016 Feb 16;2(2):CD009310. doi: 10.1002/14651858.CD009310.pub2.
2
Infections in myelodysplastic syndromes.骨髓增生异常综合征中的感染。
Haematologica. 2012 Oct;97(10):1459-70. doi: 10.3324/haematol.2012.063420. Epub 2012 Jun 24.
3
New treatments for myelodysplastic syndromes.骨髓增生异常综合征的新疗法。

本文引用的文献

1
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.流式细胞术评分系统作为骨髓增生异常综合征患者移植后预后指标的验证
Blood. 2008 Oct 1;112(7):2681-6. doi: 10.1182/blood-2008-05-153700. Epub 2008 Jul 7.
2
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.促红细胞生成素和粒细胞集落刺激因子治疗与骨髓增生异常综合征患者生存率提高相关。
J Clin Oncol. 2008 Jul 20;26(21):3607-13. doi: 10.1200/JCO.2007.15.4906. Epub 2008 Jun 16.
3
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.
Mediterr J Hematol Infect Dis. 2010 Aug 11;2(2):e2010021. doi: 10.4084/MJHID.2010.021.
4
Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study.骨髓增生异常综合征和急性髓系白血病强化诱导化疗后的门诊管理：一项试点研究。
Haematologica. 2011 Jun;96(6):914-7. doi: 10.3324/haematol.2011.040220. Epub 2011 Mar 10.
5
Myocardial remodeling: cellular and extracellular events and targets.心肌重构：细胞和细胞外事件及靶点。
Annu Rev Physiol. 2011;73:47-68. doi: 10.1146/annurev-physiol-012110-142230.
利用北美癌症登记协会（NAACCR）和监测、流行病学与最终结果（SEER）项目的数据，对2001 - 2004年美国骨髓增生异常综合征和慢性骨髓增殖性疾病的流行病学进行研究。
Blood. 2008 Jul 1;112(1):45-52. doi: 10.1182/blood-2008-01-134858. Epub 2008 Apr 28.
4
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.影响接受免疫抑制治疗的骨髓增生异常综合征患者反应和生存的因素。
J Clin Oncol. 2008 May 20;26(15):2505-11. doi: 10.1200/JCO.2007.11.9214. Epub 2008 Apr 14.
5
Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.达贝泊汀α用于治疗未接受化疗或放疗的活动性癌症患者的贫血：一项III期、多中心、随机、双盲、安慰剂对照研究的结果
J Clin Oncol. 2008 Mar 1;26(7):1040-50. doi: 10.1200/JCO.2007.14.2885. Epub 2008 Jan 28.
6
Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.使用铁螯合疗法改善骨髓增生异常综合征和铁过载患者的临床结局。
Leuk Res. 2007 Dec;31 Suppl 3:S7-9. doi: 10.1016/S0145-2126(07)70460-5.
7
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.促红细胞生成素和粒细胞集落刺激因子治疗骨髓增生异常综合征的反应和生存预测因素：GFM研究经验
Blood. 2008 Jan 15;111(2):574-82. doi: 10.1182/blood-2007-06-096370. Epub 2007 Oct 16.
8
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.来那度胺用于除5q缺失外其他核型的输血依赖型、低危和中危-1型骨髓增生异常综合征的2期研究。
Blood. 2008 Jan 1;111(1):86-93. doi: 10.1182/blood-2007-01-068833. Epub 2007 Sep 24.
9
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.接受异基因造血细胞移植的急性髓系白血病或骨髓增生异常综合征患者基于合并症和疾病状态的结局风险分层
J Clin Oncol. 2007 Sep 20;25(27):4246-54. doi: 10.1200/JCO.2006.09.7865. Epub 2007 Aug 27.
10
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.用于预测骨髓增生异常综合征患者生存及白血病演变的时间依赖性预后评分系统。
J Clin Oncol. 2007 Aug 10;25(23):3503-10. doi: 10.1200/JCO.2006.08.5696.